FDA Recalls Levothyroxine Thyroid Medication Due to Low Potency

Major Pharmaceuticals is recalling levothyroxine tablets across the United States after detecting that certain lots contain less than the required amount of the active ingredient. The medication is less potent than labeled, a deficit that may prevent patients from receiving the correct dose to treat hypothyroidism, according to reports from Infobae and Telemundo San Antonio.

The Risk of Sub-Potent Dosing

Levothyroxine is a synthetic version of the thyroid hormone T4, used to treat an underactive thyroid. It is a delicate balance. Because the drug has a narrow therapeutic index, small changes in the amount of active ingredient can lead to significant fluctuations in thyroid hormone levels in the bloodstream, El Diario NY reports.

The U.S. Food and Drug Administration (FDA) is overseeing the recall. As reported by qz.com, the agency identified the potency issue, leading to the removal of specific lots from the market to ensure patient safety and treatment efficacy.

Identifying Affected Medication

Patients using levothyroxine for hypothyroidism are advised to check their medication packaging against the affected lot numbers provided by the manufacturer. Publimetro México reports that the recall is a national effort in the U.S. to mitigate the risk of under-treatment.

Symptoms of Thyroid Imbalance

Hypothyroidism occurs when the thyroid gland does not produce enough thyroid hormone. If a patient receives a sub-potent dose of levothyroxine, they may experience a return of hypothyroid symptoms. These typically include fatigue, weight gain, cold intolerance, and dry skin, according to health context provided by El Diario NY.

Guidance for Patients and Providers

Do not stop taking the medication abruptly. Medical professionals emphasize this caution. According to guidance cited by El Diario NY, individuals who find they are using a recalled lot should contact their healthcare provider immediately to coordinate a replacement and determine if a dosage adjustment or blood test is necessary to verify current hormone levels.

Failure to Meet Pharmaceutical Standards

The recall affects tablets distributed by Major Pharmaceuticals. The company is tasked with notifying distributors and pharmacies to remove the sub-potent lots from inventory. As noted by Infobae, the specific potency deficit means the tablets do not meet the official standards for the active pharmaceutical ingredient required for this specific hormone replacement therapy.

Precision is everything. Because levothyroxine is often prescribed in very precise microgram doses, any deviation in the active principle can disrupt the metabolic balance of the patient, according to reporting from Telemundo San Antonio.